Gilead Sciences traded at $62.21 this Wednesday June 29th, decreasing $0.62 or 0.99 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences lost 4.07 percent. Over the last 12 months, its price fell by 9.66 percent. Looking ahead, we forecast Gilead Sciences to be priced at 61.38 by the end of this quarter and at 56.56 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
62.21
Daily Change
-0.99%
Yearly
-9.66%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 152.49 -0.65 -0.42% 35.79%
Acorda Therapeutics 0.46 -0.03 -5.71% -90.49%
Agios Pharmaceuticals 22.61 -0.54 -2.33% -57.76%
ALKERMES 30.39 0.62 2.08% 25.06%
Alnylam Pharmaceuticals 142.20 -4.29 -2.93% -14.27%
Amgen 243.51 -1.34 -0.55% 0.43%
Biogen 202.51 -11.06 -5.18% -41.42%
Bluebird Bio 4.04 -0.25 -5.83% -86.57%
BioMarin Pharmaceutical 83.15 -1.94 -2.28% -0.37%
Bristol-Myers Squibb 78.70 -1.28 -1.60% 18.76%
Coherus Biosciences 7.35 -0.28 -3.67% -47.65%
Gilead Sciences 62.21 -0.62 -0.99% -9.66%
GlaxoSmithKline 1,766.00 1.80 0.10% 23.88%
Glaxosmithkline 43.35 -0.35 -0.80% 8.51%
Intercept Pharmaceuticals 13.00 -0.48 -3.56% -38.36%
Incyte Corp 75.63 -1.73 -2.24% -10.71%
J&J 176.94 -5.18 -2.84% 7.87%
Eli Lilly 317.62 -9.65 -2.95% 38.48%
Merck & Co 91.89 -2.52 -2.67% 19.01%
Moderna Inc 142.19 -3.17 -2.18% -39.35%
Neurocrine Biosciences 96.93 -3.00 -3.00% -0.01%
Novartis 81.14 -0.90 -1.10% -4.06%
Puma Biotechnology 2.78 -0.11 -3.81% -69.04%
Pfizer 50.66 -1.22 -2.35% 29.57%
PTC Therapeutics 39.94 -0.11 -0.27% -4.95%
Regeneron Pharmaceuticals 594.42 -7.98 -1.32% 8.87%
Sanofi 99.37 -0.22 -0.22% 12.50%
Sangamo BioSciences 4.09 -0.18 -4.22% -65.10%
Sarepta Therapeutics 74.67 -1.63 -2.14% -5.27%
Teva Pharmaceutical Industries 7.83 -0.38 -4.63% -21.93%
United Therapeutics 234.02 -7.12 -2.95% 32.21%
Vertex Pharmaceuticals 276.17 -11.15 -3.88% 40.34%

Indexes Price Day Year
US500 3833 -78.56 -2.01% -10.80%
USND 11182 -343.01 -2.98% -23.04%
USNDX 11716 -370.47 -3.09% -19.50%

Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.